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Abstract
A standard acute toxicity study was undertaken to assess 2’-deoxyribonucleoside
cyanoboranes for therapeutic safety. 2’-Deoxyribonucleoside cyanoboranes and related
derivatives were nontoxic at doses required for anti-neoplastic and hypolipidemic activities.
At higher doses (50 and 100 mg/kg/day IP for 7 days), all treated animals survived with
slight reductions in total body weight and small decrements in daily food consumption. No
clinical chemistry value was elevated to a magnitude suggesting onset of organ specific
toxicity. However, agents appeared to modulate subpopul/tions of white blood cells, i.e.__,
more lymphocytes than PMNs were present in blood from treated animals as determined by
differential cell counts. This modulation is correlated with increases in granulomatous loci in
the spleen and mesentery of treated animals after 7 days. The kidney was damaged only by
Compound _5 at 50 and 100 mg/kg/day; Compound _5 had the most potent anti-neoplastic
activity. The compounds demonstrated no in vitro toxicity against human HCT-8 ileum cells.
LDs0 values were greater than 1000 mg/kg, IP, for all compounds.
Introduction
2’-Deoxyribonucleoside cyanoboranes have been investigated for eytotoxic activity
against murine and human tumor cell growth, and for their anti-neoplastic activity against
murine tumors [1,2]. They have also recently been observed to be hypolipidemic agents,
significantly inhibiting enzymes involved in de novo lipid synthesis [3]. Moreover, these
same derivatives were recently shown to protect against LPS-induced septic shock. The
guanine and cytidine derivatives have proven to be pharmacologically more active than some
of the other bases, inosine, adenine, or thymidine [ 1 ]. The 8 and 20 mg/kg/day doses
used in these pharmacological screens demonstrated no deleterious effects in intact animals
[ 1-3]. Thus we have selected 20 mg/kg as the standard therapeutic dose. Because of their
possible therapeutic value, five 2’-deoxyribonucleoside cyanoboranes were selected to assess
acute toxicity in mice in vivo. Deleterious effects were evaluated at dosage levels of 20, 50,
and 100 mg/kg and also in HCT-8 human ileum mucosa cells grown in tissue culture.
Materials & Methods
Compounds _1-_5 (Fig. 1), have been synthesized previously; chemical and physical
characteristics have been reported [1,2]. Suspensions of compounds were prepared by
homogenizing them in 0.05% Tween 80/H20. Controls received injections of vehicle
throughout the 7-day experiment.
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Figure 1. Structures of 2’-Deoxyribonucleoside and Cyanoborane Derivatives.
CF1 male mice (---28 g, N=5) were dosed with Compounds 1-...5 at 20, 50, and 100
mg/kg/day IP for 7 days [4]. Blood was obtained from the carotid artery and centrifuged at
3500 g x 10 min to obtain serum. Daily food consumption was determined; water was
available ad libitum. Animals were maintained in 12 h light:dark cycles at 72OF.
At the time of sacrifice, the final body weight was obtained and the major organs
were excised, trimmed of fat and weighed. Chemical or enzymatic assays were performed
with Sigma Chemical kits (St. Louis, MO, USA): urea nitrogen (BUN, No. 640), alanine
amino transferase (SGPT, No. 505), glucose (No. 510), creatine phosphokinase (CP-kinas,
No. 661), lactic dehydrogenase (LDH, No. 500), total and direct bilimbin (No. 605),
aldolase (No. 752), calcium (No. 587 and Arsen A20 111), and alkaline phosphatase (AP,
No. 104). Serum cholesterol was determined by the method of Ness et al. [5]. Serum
triglycerides were determined with a diagnostic kit from Boehringer Mannheim (Diagnostics,
Indianapolis, IN, USA). Uric acid and cholic acid were determined as outlined by Tietz [6].
Albumin and total protein were determined by the method ofLowry, et. [7].
After blood was obtained from the carotid artery of each CF 1 mouse, it was placed
on a glass slide and fixed in Wright’s stain. Differential white blood cell counts, platelet
counts and hematocrits were obtained aRer sacrificing each group at the specified times [8].
After adminstration of each dose of the 5 compounds or their respective controls,
CF 1 mice were killed by carbon dioxide asphyxiation. After all vital signs had ceased, a
midline incision was made from the lower jaw to the inguinal area. The spleen, liver, and
kidney were excised and weighed, and then representative tissue samples (6 sections
randomly selected from each group) were fixed in 10% buffered formalin, trimmed and
sectioned at 6Ix in thickness and stained with hematoxylin and eosin. Abnormal
histological/morphological findings were ascertained with light microscopy.
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To evaluate in vitro toxicity, HCT-8 human ileum cells (American Tissue Culture
Cells) were maintained in RPMI-1640 supplemented with L-glutamine, 10% fetal calf serum
(FCS) and penicillin/streptomycin (P/S) and incubated for 18 hr with agents at 10-4 M. Cell
growth was determined by 2% crystal violet in 20% MeOH [9]. Growth in the wells was
determined at 580 nm in a Molecular Devices scanner (SOFTmax Program). The medium
was harvested and the following enzyme activities were determined: lactic dehydrogenase
[ 10], AP [ 11,12], trypsin [ 13], leucine amino peptidase [ 14], ct-galactosidase [9,15], and
cAMP (125I-RIA-New England Nuclear kit). Protein levels were determined by the Lowry
et al. method [7].
To evaluate in vivo toxicity, compounds 1-.__5 were administered to CF 1 male mice as
a single injection IP at 100, 250, 500, 1000, 1500, and 2000 mg/kg. Six mice received each
dose. Mice were weighed daily and the number of deaths was recorded each day during a
14-day period [ 16]. LD50 values were determined by the Probit procedure [ 17].
Student’s "t" tests were conducted between control and treatment groups. Analyses
of variance (ANOV), followed by Duncan’s multiple range tests, were conducted for
comparisons between treatment groups.
Results
After administration of Compound 1_ at 20, 50, or 100 mg/kg/day IP for 7 days, all
animals survived without decreases in daily food consumption. Total body weight decreased
as the dose increased with an approximate 15% reduction from the control values at
highest dose. The hematocfits (%) were unchanged for all doses (Table I).
Weights of the brain, lung, and thymus decreased with increasing drug doses.
Weights of the liver, spleen, heart, kidney, and small intestine did not differ from control
weights at any dose employed. Weights of the stomach, large intestine, and reproductive
organs varied with drug dose but with no obvious correlation to the dose used. Histological
examinations revealed that all kidney sections from animals treated at 20 mg/kg/day showed
multiple foci of hemorrhage in the cortex with cellular loss. No necrotic nuclei in these
sections were found. Interestingly, at the 50 and 100 mg/kg/day doses, the kidney sections
appeared normal. Spleen sections (66%) at the 20 mg/kg/day dose showed several small
fibrous plaques on the serosal surface. One-third of the spleens at the 50 mg/kg/day dose
contained fibrous plaques; and at 100 mg/kg/day, all spleen sections contained chronic
granulomatous inflammatory foci or surface fibrosal plaques. Hepatic histology from mice
administered the 20 mg/kg/day dose revealed that one-third ofthe sections had collections of
acute and chronic inflammatory cells at the portal triad. At the 50 mg/kg/day dose, one-
third ofthe livers contained at least one fibrous plaque on the serosal surface; and at the 100
mg/kg/day dose, all liver sections had one minor granulomatous focus.
Clinical chemistry values demonstrated some variability among treatment groups;
however, none ofthe changes suggested any organ specific toxicity (Table I). Compound _1
did cause a significant reduction in BUN and bilirubin levels. Elevations were observed in
serum calcium levels. CP kinase was elevated at 20 mg/kg/day, but actually decreased
markedly at 50 and 100 mg/kg/day. For the differential white blood cell count, there was a
drug-induced increase in lymphocytes and a decrease in PMNs.
Treatment with Compound 2_ resulted in all animals surviving at all three doses
(Table II). Only the 100 mg/kg/day dose reduced daily food consumption. Treated groups
showed decreases in total body weight rather than the weight increases usually seen, but the
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effect was not dose-dependent. Hematocrit (%) values did not vary in the treatment groups.
Some variability occurred in individual organ weights with some exhibiting marked
alterations; however average heart, brain, lung, stomach, and reproductive organ weights
were relatively stable. Weights of the liver and thymus increased after treatment with 100
mg/kg/day. Small intestine weights were increased at all three doses; conversely, large
intestine weights were decreased at all three doses. Histologically at the 20 mg/kg/day dose,
Table I. Acute Toxicity of13’,5’-o-bis(triisopropylsilyl)-2’-deoxyguanosine
COMPOUND 1 Control 20 mg/kg 50 mg/kg
Gene’ral
Wt. Gain over 7 Days 109.0+ 1.50 97.70+_ 1.20 101.6+ 1.30
Food Consumption 18.4+0.90 18.10+ 1.10 20.3 +0.85
Survival 5 of 5 5 of 5 5 of 5
Hematocrit 50.8+0.80 46.4+0.90 48.0+0.70
Organ Wts. (g/100 g body wt)
Brain 1.675+0.089 1.473+0.111 1.437+0.104
Heart 0.511 +0.041
Lung 0.819+0.052
Thymus 0.400+0.040
Liver 4.570+0.076
Spleen 0.318_+0.070
Kidney 1.330+0.048
Stomach 2.096+0.053
Small Intestine 5.992+0.089
Large Intestine 4.043+0.089
Reproductive Organs 1.481+0.062
Clinical Chemistry
BUN (mg/dL) 100+ 5
SGPT (nunol/min/L) 100_+7
Glucose (mg/dL) 100+ 5
CP kinase (Sigma uniffL) 100+ 5
LDH (Sigma unit/L) 100 +_6
Bilirubin (g/100 mL) I00_.+4
Cholesterol (mg/dL) 100+ 5
Triglyceride (mg/dL) 100+6
Aldolase 100+6
Uric Acid (g/100 mL) 100_+7
Calcium (mg/dL) 100+ 5
Alkaline Phosphatase 100+ 3
Otmol/min/L)
Choli Acid (mg/dL) 100+_.4
Total Protein (g/100 mL) 100_+ 5
Differential White Blood Cells (%)
0.526+ 0.054 0.548__+0.036
0.751 +0.058 0.739+ 0.052
0.377 +__0.032 0.364+ 0.038
5.200+0.064 5.245+0.062
0.496+0.062 0.455+0.079
1.378 +__0.049 1.383+0.057
1.529+ 0.062* 1.928+ 0.068
5.011 +0.092 5.865 + 0.086
3.942 +0.076 3.824+0.072
1.871 + 0.052 2.093+0.051"
Lymphocytes 57%+_5
PMNs 42%+ 5
Basophils 1%+ 1
Eosinophils 0%+0
Mncytes 0%+0
P < 0.001
100 mg/kg
94.6+ 1.4
19.2+ 1.2
5of5
47.2+0.5
1.381+0.098
0.569+0.039
0.612+0.064
0.248+0.035*
5.428+0.079
0.656+0.083
1.328+0.041
2.699+0.059*
5.934_+0.081
4.427+ 0.064
2.257+ 0.068*
79+4* 98+5 79+6*
100+7 100+6 99+5
101_+ 5 86+7 102+6
145+5" 60+5* 61+4"
59+6* 68+4* 121+3
67+4* 91 +6 88+4
68+6* 106+6 104+5
93+3 101+_5 110+6
87+5 92+6 91+6
103+ 4 122+7 95+ 5
137+7 132+_6 123+4
96+6 102+5 102+3
98+5 126+_ 11 113+4
94+ 5 101 +4 83+ 5
65%+5
23%+3
0%+0
o%+_0
1%+0
73%+_5
25%+4
1%+0
0%+0
1%+0
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33% of the mesenteric mesenchymal and fatty tissues contained exudates consisting of
macrophages and lymphocytes with a few PMNs. At the 50 mg/kg/day dose, one hepatic
section contained a few granulomatous foci. All other sections were normal, particularly at
the 100 mg/kg/day dose ofCompound 2_.
The lack ofchanges in clinical chemistry values suggests that Compound 2_ caused no
organ toxicity (Table II). Bilirubin, cholesterol, and adolase levels were reduced in a dose-
Table H. Acute Toxicity of 2_, 3’,5’-o-bis(triisopropylsilyl)-2’-deoxyguanosine-N7-
cyanoborane
COMPOUND 2 Control
General
Wt. Gain over 7 Days 101.6+ 1.70
Food Consumption 12.6+ 0.90
Survival 5 of 5
Hematocrit 50.3 + 1.2
20 mg/kg/day 50 mg/kg/day 100 mg/kg/day
101.6+ 1.50 100.0+ 1.10 101.7+ 1.40
12.4 + 0.85 12.4 +0.80 9.4+0.60*
5 of 5 5 of 5 5 of 5
45.8+ 1.1 46.9+ 1.3 45.3+ 1.4
Organ Wts. (g/100 g body weight)
Brain 1.620+ 0.090 1.580 + 0.087 1.540+ 0.088 1.520+ 0.082
Heart 0.510+ 0.042 0.520+ 0.045 0.490_+ 0.043 0.520+ 0.041
Lung 0.730+ 0.055 0.890+ 0.051 0.710+ 0.047 0.820+ 0.057
Thymus 0.270+ 0.038 0.240+ 0.042 0.240+ 0.031 0.370+ 0.027
Liver 5.480+ 0.076 5.950+ 0.081 5.920+ 0.071 7.260+ 0.070
Spleen 0.390+ 0.062 0.390+ 0.059 0.390+ 0.051 0.520+ 0.061
Kidney 1.440 +_ 0.045 1.460+ 0.041 1.430+ 0.042 1.600+ 0.051
Stomach 2.140+ 0.051 2.810_+ 0.059 2.600+ 0.053 2.330+ 0.061
Small Intestine 5.690+ 0.087 6.230+ 0.092 6.210+ 0.098 6.620+ 0.095
Large Intestine 5.640+ 0.065 3.790+ 0.061 3.850+ 0.042 3.710+ 0.053
Reproductive Organs 0.970+ 0.051 1.460+ 0.042* 1.110+ 0.061 1.020+ 0.071
Clinical Chemistry
BUN (mg/dL) 100+5 106+6 102+7 118.0+6
SGPT (mmol/min/L) 100+ 7 89 + 5 89+6 90.0+ 7
Glucose (mg/dL) 100+ 5 89+ 6 103 + 5 103.2+6
CP kinase (Sigma unit/L) 100+5 69_+5* 73+7* 104.7+5
LDH (Sigma unit/L) 100+6 55 + 4* 62+ 5* 115.3 + 4
Bilirubin (g/100 mL) 100+ 4 89+ 6 89+ 6 78.1 + 6
Cholesterol (mg/dL) 100+ 5 98 +_6 75+6* 65.0+ 5*
Triglyceride (mg/dL) 100+6 95 + 5 86+ 5 107.0+ 6
Aldolase 100+6 94 + 5 92+ 4 76.2+ 4"
Uric Acid (g/100 mL) 100+7 109+7 114+3 110.9+6
Calcium (mg/dL) 100+ 5 179 + 6* 149+6* 107.5+ 7
Alkaline Phosphatase 100+ 3 94 + 5 127+ 3" 148.1 + 7
(ttmol/min/L)
Cholic Acid (mg/dL) 100+ 4
Total Protein (g/100 mL) 100+ 5
Differential White Blood Cell Count (%)
Lymphocytes 56%+ 4
PMNs 38%+4
Basophils 2%+ 1
Eosinophils 1%+0
3%+0
* P < 0.001
106+4 104+5 104.0+6
94 + 5 92+ 6 95.1 + 3
75%+0 82%+0
20%+0 14%+0
3%+0 2%+0
1%+0 1%+0
1%+0 1%+0
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dependent manner. CP ldnase activity and LDH levels were reduced after treatment at 20
and 50 mg/kg/day; however, these levels remained at control values in animals treated at 100
mg/kg/day. Calcium levels were elevated at 20 and 50 mg/kg/day, but remained at control
values at the 100 mg/kg/day dose. AP levels were elevated at the 50 and 100 mg/kg/day
doses. Differential white blood cell counts showed an increase in lymphocytes and a
decrease in PMNs. The small percentage changes in the other minor white blood cells were
not significant. Platelet estimates were normal for all doses.
Table HI: Acute Toxicity of 3_, 5’-Triisopropyisilyl-2’,3’-dideoxycytitidine
COMPOUND 3 Control 20 mg/kg/day $0 mg/kg/day 100 mg/kg/day
eneral
Wt. Gain over 7 Days 101.1 + 1.40 101.4_+ 1.20 102.5+ 1.00 96.7+0.90
Food Consumption 13.9+0.80 12.5 _+ 0.90 13.3 +0.90 14.7_+0.90
Survival 5 of 5 5 of 5 5 of 5 5 of 5
Hematocrit 49.7+0.90 45.0+0.80 46.7+0.40 45.4+0.80
Organ Wts. (g/100 g body weight)
Brain 1.870_+0.088 1.050+0.091 1.401 _+0.085 1.413 +0.082
Heart 0.493 _+0.047 0.506+0.042 0.616+ 0.049 0.532+ 0.039
Lung 0.692+0.051 0.749+0.045 0.692+_0.041 0.773+0.053
Thymus 0.281 +0.039 0.255+0.036 0.292+0.025 0.232+0.040
Liver 5.166+0.077 5.435+0.071 5.895+0.069 5.579+0.076
Spleen 0.426+0.068 0.435+0.062 0.521+0.053 0.484+0.049
Kidney 1.494+0.042 1.362+0.039 1.254+0.027 1.474+0.031
Stomach 2.421 +0.050 2.559+0.032 3.263 +0.029 2.535+0.036
Small Intestine 6.323 +_0.091 6.602 +0.082 6.904+0.041 6.135 +0.086
Large Intestine 4.844 +_0.062 4.749+0.061 3.600+0.059 4.524+0.068
Reproductive Organs 0.828 +_0.047 1.066+0.059 1.053 +0.042 1.772 +0.082*
Clinical Chemistry
BUN (mg/dL) 100+5 80+6* 87+5 96+3
SGPT (mmol/min/L) 100+7 100+6 107+ 7 93 + 7
Glucose (mg/dL) 100+ 5 97+ 5 96+ 6 88+ 8
CP kinase (Sigma unit/L) 100+5 98+5 113+6 68+7*
LDH (Signm unit/L) 100+6 112+7 123+ 5 154+7*
Bilirubin (g/100 mL) 100+4 100+6 118+ 5 119+6
Cholesterol (mg/dL) 100+ 5 97+ 5 86+4 76+ 4*
Triglyccdde (mg/dL) 100+6 109+6 121 +_ 5 122+6
Aldolase 100+6 97+ 4 79+ 4 53 + 5*
Uric Acid (g/100 mL) 100+ 7 111 + 5 120+6 110+ 7
Calcium (mg/dL) 100+6 100+4 96+6 148+6"
Alkaline Phosphatase 100+ 3 124+4 115+ 55 112+ 7
0tmol/min/L)
Cholic Acid (mg/dL) 100+ 4 139+ 5* 151 + 7* 111 + 7
Total Protein (g/100 mL) 100+5 97+6 98+6 93+6
Differential White Blood Cell Count (%)
Lymphocytes
PMNs
Basophils
Eosinophils
Monocles
* P_< 0.001
57%+ 4 60%+6 69%+ 6
42%+ 3 38%+ 3 25%+ 0
1%+0 1%+0 2%+0
0%+0 0%+0 2%+0
0%+_0 1%+0 2%_+0
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Survival after treatment with Compound 3_ at three dosages (20, 50, and 100
mg/kg/day) did not differ from that of controls (Table III). There was no change in daily
food consumption; however, a 15% decrease in total body weight was evident at the 100
mg/kg/day dose. The hematocrit values (%) were normal at all dosage levels.
Table IV. Acute Toxicity of 4, 3’,5’-o-bis(triisopropylsilyl)-2’-deoxycytidine
COMPOUND 4 Control
General
Wt. Gain over 7 Days 109.4+ 1.30
Food Consumption 11.5+0.9
Survival 5 of 5
Hematocrit 46.7+ 1.00
20 mg/kg/day 50 mg/kg/day 100 mg/kg/day
110.9+ 1.20 114.2+ 1.40 113.4+ 1.20
10.3__+0.8 12.5+0.9 11.8+ 1.0
5 of 5 5 of 5 5 of 5
44.8+0.80 45.0+ 0.90 44.6+ 0.90
Organ Wts. (g/100 g body weight)
Brain 1.318+0.072 1.213_+0.069 1.266+0.062 1.054+0.067
Heart 0.614+0.041 0.667+0.039 0.625+0.025 0.553+0.027
Lung 0.787+0.06 0.763+0.058 0.714+0.051 0.656+0.057
Thymus 0.269+0.027 0.304+0.022 0.209+0.019 0.279+0.033
Liver 5.986+0.056 6.196+0.059 6.207+0.063 6.693+0.034
Spleen 0.402 +0.039 0.672+0.027 0.477+0.036 0.493 +0.047
Kidney 1.937+0.047 1.875+_0.039 1.969+0.051 1.809+0.043
Stomach 2.136+0.055 2.365_+0.042 2.727+0.049 3.051 +0.061
Small Intestine 7.169+0.088 7.344_+0.08 5.453 +0.092 5.811 +0.07
Large Intestine 4.313 +0.072 3.269+0.069 4.401 +0.082 3.393 + 0.065
Reproductive Organs 2.518+0.048 2.876+0.052 2.807+0.041 2.911 +0.045
Clinical Chemistry
BUN (mg/dL) 100+5 96+5 85+4 70+5*
SGPT (mmol/min/L) 100+7 104_+6 97+6 95+7
Glucose (mg/dL) 100+ 5 104_+6 97+ 5 95+6
CP kinase (Sigma unit/L) 100+5 108+6 66+5* 108+7
LDH (Sigma unit/L) 100+6 154+ 7 116+6 113+6
Bilirubin (g/100 mL) 100+4 96+_ 3 72+ 5* 60+ 5*
Cholesterol (mg/dL) 100+5 95+ 5 107 +_.6 119+6
Triglyceride (mg/dL) 100+6 91 +6 89+ 7 91 + 7
Aldolase 100+ 6 95+6 91+6 84+ 7
Uric Acid (g/100 mL) 100+ 7 95 _+6 86+ 5 75+ 6
Calcium (mg/dL) 100+ 5 117+ 7 106+ 5 96+ 5
Alkaline Phosphatase 100+ 3 80+ 5 90+6 94+ 5
(.mol/min/L)
Cholic Acid (mg/dL) 100+4 84+6 72+ 5 53 + 4*
Total Protein (g/100 mL) 100_+5 99+7 104+6 99+6
Differential White Blood Cell Count (%)
Lymphocytes 52%+4
PMNs 45%+3
Basophils 2%+ 1
Eosinophils 0%+0
Monocles 1%+.0
* P<0.001
59%+4 71%+4
39%+3 26%_+3
1%_+0 1%+0
0%_+0 0%+0
1%+0, 1%+0
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Individual organ weights varied slightly after treatment with 3_. Weights of the liver,
stomach, thymus, heart, spleen, and small intestine did not differ from control values. Brain
weight at the 20 mg/kg/day was reduced; however, it approached control values at the 50
and 100 mg/kg/day doses. Weights of the lungs and reproductive organs increased as the
dose increased. The weight ofthe large intestine decreased at the 50 mg/kg/day dose; it was
consistent with control values at the 20 and 100 mg/kg/day doses.
Histology of liver and kidney sections after treatment with Compound 3_ at 20, 50
and 100 mg/kg/day doses was normal. However, 67% of spleen and mesenteric tissues
showed fibrotic plaques and granulomatous foci. At the 100 mg/kg/day dose, all splenic
sections with mesenteric connective tissues contained granulomatous inflammation, although
the spleen weight was normal for all doses.
Clinical chemistry values did not reveal any specific drug-related organ toxicity after
treatment with Compound 3_ (Table Ill). BUN, cholesterol, aldolas, and CP kinas were
reduced in a dose-dependent manner. LDH and tdglycedd levels were increased in a
similar fashion. AP and cholic acid levels were raised at lower doses but returned to control
values at the 100 mg/kg/day dose. In the differential white blood cell count, lymphocytes
increased while PMN levels decreased. Platelet estimates were normal at all doses.
Compound 4_ caused no changes in survival of the animals or in total body weight
increases measured after treatment for 7 days (Table IV). Although daily food consumption
was reduced slightly in mice at the 20 mg/kg/day dose, this parameter was within normal
limits at the 50 and 100 mg/kg/day doses. Similarly, hematocdt percentages did not differ
from control values.
Individual organ weights were normal for the thymus and kidney at all doses of_4.
Weights of the heart, lung, brain, small intestine, and large intestine decreased from control
values after treatment at the 100 mg/kg/day dose. Spleen weight increased after treatment at
20 mg/kg/day, but returned to control values at 50 and 100 mg/kg/day doses. Increases in
weights of the stomach and reproductive organs were directly related to dosage 1v1,
indicating a dose-response relationship. Histological examination revealed no visible
morphological lesions in the liver and kidney except in mice receiving the 50 mg/kg/day
dose. One kidney section showed minor granulomatous inflammation on the capsular
surface. Spleen sections in greater than 66% ofthe mice from all treatment groups including
the control showed minute loci ofgranulomatous inflammation on the capsular surface.
Clinical chemistry values were altered after treatment with Compound _4 (Table IV).
BUN, CP-kinase, bilirubin, uric acid, alkaline phosphatase, and cholic acid showed decreases
in values at 100 mg/kg/day. LDH values were elevated at 20 mg/kg/day, and slightly
elevated at 50 and 100 mg/kg/day. Serum cholesterol levels were elevated at 100
mg/kg/day, and calcium levels were elevated at 20 mg/kg/day. In the differential white
blood cell counts at higher drug concentrations, lymphocytes were increased and PMNs
were reduced. Platelet estimates were normal for all groups.
After treatment with Compound 5_, all of the animals survived at all three doses
employed (Table V). The total body weight increase over 7 days was reduced after
treatment with the three doses. Yet, daily food consumption was increased after treatment
with 20 and 50 mg/kg/day doses. The hematocrit (%) were normal for animals treated with
Compound _5 at all dosage levels.
Individual organ weights were altered by Compound 5_, heart, lung, and stomach
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Table V. Acute Toxicity of $_, 2’-deoxycytidine-N3-cyanoborane
COMPOUND 5
General
Wt. Gain over 7 Days
Food Consumption
Survival
Hematocrit 45.680+_0.80
Organ Wts. (g/100 g body weight)
Control 20 mg/kg/day ’50 mg/kg/day i00 mg/kg/day’"
113.8_+ 1.30 110.1 + 1.20 104.6+ 1.40 106.7+ 1.30
18.9+_0.80 22.9+ 1.20 22.9+ 1.10 18.9+ 1.00
5 of 5 5 of 5 5 of5 5 of 5
43.906+0.60 45.519+0.70 44.876+0.80
Brain 1.356+0.088 1.489+0.071 1.335+0.069 1.222+0.032
Heart 0.555+0.043 0.476+0.048 0.372+0.051 0.576+0.050
Lung 0.875+0.056 0.759+0.052 0.810+0.048 0.829+0.053
Thymus 0.229+0.027 0.287+0.025 0.240+0.021 0.286+0.029
Liver 5.211 +0.065 5.930+0.059 5.888+0.061 6.046+0.062
Spleen 0.426_+0.062 0.621 +0.055 0.577+0.069 0.590+0.053
Kidney 1.788_+0.047 1.866+0.041 1.906+0.051 2.011 +_0.049
Stomach 1.907+0.048 1.790+0.056 1.919+0.038 2.142 +0.053
Small Intestine 6.140+0.077 4.283+0.071 5.907+0.065 4.608+0.069
Large Intestine 4.539+0.057 4.864+0.047 4.400+0.071 4.483 +0.067
Reproductive Organs 2.354+0.062 2.321 +0.051 2.847+0.059 2.484 +0.077
Clinical Chemistry
BUN (mgtdL) 100+5 63 +4" 86+ 3 92+6
SGPT (mmol/min/L) 100+7 100+6 99+7 101+5
Glucose (mg/dL) 100+5 98+ 5 99+4 88+5
CP kinase (Sigma unit/L) 100+5 45+5* 84+5 37+4
LDH (Signm unit/L) 100+6 84+7 88+6 86+5
Bilirubin (g/100 mL) 100+4 94+6 70+6 96+6
Cholesterol (mg/dL) 100 +_ 5 92+ 5 86+5 101 + 7
Triglyceride (mg/dL) 100+6 98+ 7 77+6 88+6
Aldolase 100+6 42+ 5* 55+7* 43 + 4
Uric Acid (g/100 mL) 100+7 73+6* 75+5 115+5
Calcium (mg/dL) 100+ 5 97+ 7 105+6 106+4
Alkaline Phosphatase 100+ 3 122+6 148+5* 136+6
(rtmol/min/L)
Cholic Acid (mg/dL) 100 +_4 86+ 5 99+6 94+5
Total Protein (g/100 mL) 100+5 95+4 108+7 107+6
Differential White Blood Cell Count (%)
Lymphocytes 56%+4 58%+ 4 64%+4 56%+ 5
PMNs 38%+_4 40%+4 34%+2 41%+ 4
Basophils 2%+_0 1%+_0 1%_+0 2%+_0
Eosinophils 1%+0 0%+0 0%+0 1%+0
Monocytes 3%+ 1 1%+0 1%+0 0%+0
Rouleux formation No No No Yes
* P < 0.001
weights were reduced at 20 mg/kg/day; these weights returned to normal values at the 50
and 100 mg/kg/day doses. The brain and small intestine were reduced in weight after
treatment with the 100 mg/kg/day dose. Weights of the liver, spleen, kidney and the
reproductive organs were increased; however, these generally did not follow a dose-
response relationship. Hepatic morphological alterations were not visible after treatment
with Compound _5 at either the 20, 50, or 100 mg/kg/day dose, IP for 7 days. After
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treatment at 100 mg/kg/day, 66% of the sections of the spleen contained perisplenie
connective tissue with one focus of red blood cells. At the 20 mg/kg/day dose, one kidney
section had a small granulomatous focus in the mesenterie connective tissue. The cortical
surface ofthe kidney contained one small fibrous plaque and one granulomatous focus. The
remainder of the kidneys were normal. At the 50 mg/kg/day dose of Compound _5, kidneys
showed enlarged pelvic regions lined with transitional epithelial cells with a concomitant
cellular loss in the medullar regions. Renal papillae were not seen. Connective tissue at the
hilar area had collections of red blood cells (hemorrhagic), which may have been due to
post-mortem changes. After 100 mg/kg/day, all kidneys demonstrated changes in the pelvic,
medullary, and hilar regions similar to those observed after the 50 mg/kg/day dose.
Serum clinical chemistry values were not elevated after treatment with Compound _5
with the exception ofAP, which peaked in mice receiving the 50 mg/kg/day dose. BUN, CP
ldnase, aldolase, and uric acid levels were reduced significantly at the 20 mg/kg/day dose.
Bilirubin levels were reduced in mice receiving the 50 mg/kg/day dose only. Differential
white blood cell counts and platelet estimates did not differ from control values for all
treatment groups.
Histology of the control animal receiving only the vehicle showed that all the liver
sections were normal. The spleen sections showed a few loci of granulomatous
inflammation on the capsular surface. One kidney section from a control animal showed a
small fibrous plaque on the cortex. These findings were considered incidental.
Enzymatic patterns indicating toxicity in HCT-8 (human small intestine ileum
mucosa) cultured cell growth were not altered after incubating these cells with Compounds
1-5 at 10-4 M (Table VI). Activities of t-glucouronidase, LDH, AP, and trypsin did not
differ from control values in both the cell preparation and the medium. No evidence that
mucosal villa enzymes leaked from the cells due to drug-induced toxicity was found.
Moreover, cytotoxicity was not evident after incubation with the agents at 10-4 M. LD50
values for the five compounds in mice were all greater than 1000 mg/kg, IP. Further testing
was difficult because ofthe limited solubility ofthe compounds.
Table VI. The Effects of 2’Deoxyribonucleoside Cyanoboranes on Human HCT-8
Ileum Growth and Enzyme Activities Related to Organ-Specific Toxicity
Percent of Control (Mean :l: SD)
N---6 Growth tz-Galactosidase Alkaline LDH Trypsin Protein
ComPound (Crystal Violet) Phosphatase BAEE Levels
1 116+ 5 108+ 7 101+ 6 90+ 4 100+ 6 104+ 5
2 114+ 6 97+ 6 90+ 6 95+ 5 99+ 5 89+ 4
3 101+ 6 95+ 7 85+ 5 98+ 5 100+ 5 113+ 5
4 98+ 5 113+ 6 89+ 5 93+ 4 102+ 6 100+ 6
5 99+ 5 95+ 4 96+ 8 93+ 4 101+ 6 119+ 5
Control 100_+ 6 100_+ 5 100+ 6 100+ 5 11)0+ 6 100+ 6
Discussion
Administration of 2’deoxyribonucleoside cyanoboranes was not toxic to the survival
of CF 1 mice. The therapeutic dose of these derivations has been established at 8 and 20
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mg/kg/day for anti-neoplastic [ 1,2] and hypolipidemic activity [3]. With all five compounds,
very few measured parameters were altered in a way to suggest that this low dose would be
toxic under therapeutic conditions.
None of the total body weight and individual organ weight changes at the doses
employed for any of the five compounds would be inconsistent with survival of the animals.
The clinical chemistry values were not elevated to levels suggesting organ damage induced
by the 2’deoxyribonucleoside cyanoboranes. Only treatment with Compound _5 at 100
mg/kg/day suggested any organ-specific toxicity to the kidney, as revealed by histological
examination.
The HCT-8 ileum culture assay also indicated that Compounds 1-_5 caused no
enzymatic leakage from the cells which would suggest organ-specific drug toxicity. The
hematocrit (red blood cells) and platelet estimates were normal, suggesting no major effects
on the bone marrow hematopoietic system. However, all compounds showed some effects
on the differential white blood cell count. In the white blood cell population, more
lymphocytes were observed, whereas PMNs were lowered. The total white blood cell
population did not appear to be reduced by the agents. Rather, the drug stimulated a shift to
more lymphocytes, perhaps in response to the observed increase in inflammation around the
spleen mesenteric connective tissue and connective tissue. Perhaps the agents have an
immunomodulatory activity that may explain these shifts in white blood cell populations.
The cyanoborane group did not appear to be related to observed histological changes
since few changes were observed with Compound 1_, which did not contain the cyanoborane
moiety. Yet histological examination of tissues after treatment with Compound 2, which
contained the cyanoborane moiety and two triisopropylsilyl protecting groups, showed
numerous foci of inflammation. However, the parenchymal sections of the organs were
generally normal, indicating that the protecting group probably caused no observable tissue
damage.
Compounds 3_ and 4_, cytidine derivatives with triisopropylsilyl protecting groups but
no cyanoborane group, demonstrated extensive infection ofthe spleen and mesentery around
the organ. Yet only _5, which contained a cyanoborane group, demonstrated extensive
damage to the kidney medullary region and papillae with no damage to liver and spleen.
Among the five derivatives tested, Compound _5 was the most active anti-neoplastic agent.
It is not unusual for anti-neoplastic agents to cause kidney toxicity, particularly those
containing metal complexes, cis-platinum. Since the boron atom is not considered a
heavy metal in the classical sense, it can be inferred that the cyano group caused kidney
toxicity. It is interesting to note that the cyanoborane on the guanine 2_ did not cause
nephrotoxicity, whereas the cytidine derivative _5 was toxic to the kidney. Kidney toxicity
was not accompanied by concurrently increased levels ofBUN at any dose ofCompound 5_,
which was a peculiar finding. Clinical chemistry values are thought to change before
morphological lesions are observable.
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